Vistagen Therapeutics Files 8-K
Ticker: VTGN · Form: 8-K · Filed: Jan 14, 2025 · CIK: 1411685
| Field | Detail |
|---|---|
| Company | Vistagen Therapeutics, Inc. (VTGN) |
| Form Type | 8-K |
| Filed Date | Jan 14, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, 8-k, regulatory
Related Tickers: VTGN
TL;DR
VTGN filed an 8-K on Jan 14, 2025, mostly procedural stuff.
AI Summary
On January 14, 2025, Vistagen Therapeutics, Inc. filed an 8-K report. The filing primarily concerns other events and financial statements/exhibits, with no specific material event detailed in the provided text. The company is incorporated in Nevada and its principal executive offices are located in South San Francisco, California.
Why It Matters
This filing indicates Vistagen Therapeutics is providing updates or submitting required financial documentation to the SEC, which is standard for publicly traded companies.
Risk Assessment
Risk Level: low — The filing is a routine 8-K for 'Other Events' and financial exhibits, not indicating any immediate material adverse or positive developments.
Key Numbers
- 0001411685-25-000007 — Accession Number (Unique identifier for the filing)
- 001-37761 — SEC File Number (Company's SEC file number)
Key Players & Entities
- Vistagen Therapeutics, Inc. (company) — Registrant
- Nevada (jurisdiction) — State of incorporation
- South San Francisco, California (location) — Principal executive offices
- January 14, 2025 (date) — Date of report
FAQ
What is the primary purpose of this 8-K filing by Vistagen Therapeutics?
The filing is primarily for 'Other Events' and 'Financial Statements and Exhibits', indicating routine updates or submissions to the SEC.
When was this 8-K report filed?
The report was filed on January 14, 2025.
Where are Vistagen Therapeutics' principal executive offices located?
The principal executive offices are located at 343 Allerton Ave., South San Francisco, California, 94080.
In which state is Vistagen Therapeutics incorporated?
Vistagen Therapeutics, Inc. is incorporated in Nevada.
What is the company's IRS Employer Identification Number?
The IRS Employer Identification Number is 205093315.
Filing Stats: 488 words · 2 min read · ~2 pages · Grade level 12.3 · Accepted 2025-01-14 17:16:28
Key Financial Figures
- $0.001 — ich registered Common Stock, par value $0.001 per share VTGN Nasdaq Capital Market
Filing Documents
- vtgn-20250114.htm (8-K) — 24KB
- ex-991ph284phase2pr20250114.htm (EX-99.1) — 19KB
- imagea.jpg (GRAPHIC) — 10KB
- 0001411685-25-000007.txt ( ) — 183KB
- vtgn-20250114.xsd (EX-101.SCH) — 2KB
- vtgn-20250114_lab.xml (EX-101.LAB) — 21KB
- vtgn-20250114_pre.xml (EX-101.PRE) — 12KB
- vtgn-20250114_htm.xml (XML) — 3KB
01 Other Events
Item 8.01 Other Events On January 14, 2025, Vistagen Therapeutics, Inc. (the " Company ") issued a press release to announce positive results from an exploratory Phase 2A study of its investigational pherine nasal spray, PH284, in cancer cachexia. In the study, PH284 demonstrated higher mean subjective feeling of hunger as compared to placebo and appeared safe and well-tolerated with an adverse event profile similar to placebo in a population compromised by terminal cancer. A copy of the press release is attached to this Current Report on Form 8-K as Exhibit 99.1.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits (d) Exhibits Index Exhibit No. Description 99.1 Press Release issued by Vistagen Therapeutics, Inc., dated January 1 4 , 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
Signatures
Signatures Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Vistagen Therapeutics, Inc. Date: January 14, 2025 By: /s/ Shawn K. Singh Shawn K. Singh President and Chief Executive Officer